Skip to main content
Equibles
BBOT logo

BBOT · BridgeBio Oncology Therapeutics, Inc.

Track BBOT — free

Use BBOT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BBOT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.95 -0.57 (-10.33%) At close · Sep 11
Rebalance outlook locked
Market Cap
$399.67M
Shares
80.17M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.95 Open$5.53 Day$4.90–5.62 52W close$4.95–13.73 Avg vol 30d426K Short int6.2M · 7.7% float · 20.8d Short vol37% Last earningsJan 7, 2026 DataFeb 2024–Sep 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$182.11M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-37.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$225.71M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+59.5%
Year over year · more shares
Price change (1Y)
-45.1%
Trailing year
Short interest
7.7%
Latest settlement · 20.8 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −49%
below
Price vs 50-day avg −43%
below
RSI (14) 17
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −46%
trailing
6-month return −43%
trailing
YTD return −60%
this year
Relative strength −61%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +16 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.73% of float · ▲ +6.6% MoM · 20.8 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
65 holders — near 2-yr high, broad support
Squeeze score 61
elevated · 0–100
Fundamentals
Fair
EPS growth +100%
Y/Y
Free cash flow $-114.5M
Quant / Vol
risk profile
Very High
Volatility 70%
annualized · 1-yr
Max drawdown −64%
past year
ATR 13.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−49% Bearish
Price vs 50-day avg
−43% Bearish
RSI (14)
17 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +16 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.73% of float · ▲ +6.6% MoM · 20.8 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
65 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $5 · 0% Range high $14
vs 200-day avg -49% vs 50-day avg -43%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BBOT
BridgeBio Oncology Therapeutics, Inc.
this stock
$399.67M -60.5% — — 7.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
65
% held
73.7%
Net QoQ
+1.7M sh
Top holder
Cormorant Asset Managemen…
Held Float
View
Held by Funds
Fund positions
42
View
Short & Settlement
Short Interest Rising
Shares short
6.2M
Days to cover
20.8d
Change
+385.3K sh
View
Short Volume
Short vol %
37%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
9.1K
Value
$83.3K
As of
Aug 12, 2026
View
Off-Exchange
Off-exchange %
30.0%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-134.0M
EPS diluted
$-4.30
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 8, 2026
This year
13
View
Earnings & Events
Earnings Calls
Last call
Jan 7, 2026
View

Performance

5D 20D 120D MTD YTD
BBOT -44.4% -46.4% -43.0% -43.8% -60.5%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -43.2% -44.6% -60.8% -43.4% -72.5%
Key facts CIK 1869105 CUSIP 107924102 13F (30d) 51 filings 51 filers Visit website Investor relations